Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.30
ALXN's Cash to Debt is ranked lower than
91% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. ALXN: 0.30 )
Ranked among companies with meaningful Cash to Debt only.
ALXN' s Cash to Debt Range Over the Past 10 Years
Min: 0.3  Med: 2.90 Max: No Debt
Current: 0.3
Equity to Asset 0.63
ALXN's Equity to Asset is ranked lower than
57% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ALXN: 0.63 )
Ranked among companies with meaningful Equity to Asset only.
ALXN' s Equity to Asset Range Over the Past 10 Years
Min: 0.04  Med: 0.67 Max: 0.95
Current: 0.63
0.04
0.95
Interest Coverage 8.44
ALXN's Interest Coverage is ranked lower than
81% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALXN: 8.44 )
Ranked among companies with meaningful Interest Coverage only.
ALXN' s Interest Coverage Range Over the Past 10 Years
Min: 11.24  Med: 136.04 Max: 292.93
Current: 8.44
11.24
292.93
F-Score: 4
Z-Score: 4.22
M-Score: -2.12
WACC vs ROIC
11.82%
1.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 22.14
ALXN's Operating margin (%) is ranked higher than
87% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. ALXN: 22.14 )
Ranked among companies with meaningful Operating margin (%) only.
ALXN' s Operating margin (%) Range Over the Past 10 Years
Min: -8798.78  Med: 25.18 Max: 38.89
Current: 22.14
-8798.78
38.89
Net-margin (%) 5.37
ALXN's Net-margin (%) is ranked higher than
75% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. ALXN: 5.37 )
Ranked among companies with meaningful Net-margin (%) only.
ALXN' s Net-margin (%) Range Over the Past 10 Years
Min: -8441.21  Med: 17.12 Max: 76.31
Current: 5.37
-8441.21
76.31
ROE (%) 1.98
ALXN's ROE (%) is ranked higher than
77% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. ALXN: 1.98 )
Ranked among companies with meaningful ROE (%) only.
ALXN' s ROE (%) Range Over the Past 10 Years
Min: -136.75  Med: 14.48 Max: 63.11
Current: 1.98
-136.75
63.11
ROA (%) 1.28
ALXN's ROA (%) is ranked higher than
79% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. ALXN: 1.28 )
Ranked among companies with meaningful ROA (%) only.
ALXN' s ROA (%) Range Over the Past 10 Years
Min: -45.22  Med: 9.66 Max: 46.71
Current: 1.28
-45.22
46.71
ROC (Joel Greenblatt) (%) 57.00
ALXN's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. ALXN: 57.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALXN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -509.26  Med: 54.85 Max: 173.86
Current: 57
-509.26
173.86
Revenue Growth (3Y)(%) 28.30
ALXN's Revenue Growth (3Y)(%) is ranked higher than
81% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. ALXN: 28.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALXN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.5  Med: 38.80 Max: 462.4
Current: 28.3
-68.5
462.4
EBITDA Growth (3Y)(%) 15.20
ALXN's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ALXN: 15.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALXN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.7  Med: 21.95 Max: 73.2
Current: 15.2
-10.7
73.2
EPS Growth (3Y)(%) -19.50
ALXN's EPS Growth (3Y)(%) is ranked lower than
66% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. ALXN: -19.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALXN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.5  Med: 10.90 Max: 76.4
Current: -19.5
-19.5
76.4
» ALXN's 10-Y Financials

Financials (Next Earnings Date: 2016-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ALXN Guru Trades in Q3 2015

Jim Simons 689,542 sh (+5029.76%)
David Carlson 160,000 sh (unchged)
Pioneer Investments 32,062 sh (unchged)
Mario Gabelli Sold Out
Lee Ainslie Sold Out
David Swensen Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
Frank Sands 6,379,857 sh (-2.14%)
Ron Baron 32,624 sh (-53.24%)
» More
Q4 2015

ALXN Guru Trades in Q4 2015

Louis Moore Bacon 30,000 sh (New)
Ron Baron 61,177 sh (+87.52%)
Pioneer Investments 41,785 sh (+30.33%)
David Carlson 160,000 sh (unchged)
Samuel Isaly 223,000 sh (unchged)
Jim Simons Sold Out
Frank Sands 6,056,762 sh (-5.06%)
» More
Q1 2016

ALXN Guru Trades in Q1 2016

Joel Greenblatt 10,684 sh (New)
Steven Cohen 85,700 sh (New)
John Paulson 157,200 sh (New)
Dodge & Cox 1,820 sh (New)
David Carlson 160,000 sh (unchged)
Samuel Isaly 223,000 sh (unchged)
Louis Moore Bacon Sold Out
Pioneer Investments 41,290 sh (-1.18%)
Ron Baron 55,950 sh (-8.54%)
Frank Sands 5,211,879 sh (-13.95%)
» More
2016

ALXN Guru Trades in 2016

Spiros Segalas 2,553,911 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NYSE:BXLT, NAS:VRTX, OTCPK:SHPGF, OTCPK:ALIOY, NAS:INCY, OTCPK:CSLLY, NAS:REGN, NAS:BMRN, OTCPK:GIKLY, OTCPK:NVZMY, OTCPK:UCBJY, NAS:MDVN, OTCPK:GMXAY, NAS:JAZZ, NAS:ALKS, NAS:SGEN, NAS:ALNY, NAS:UTHR, OTCPK:SBMFF, NAS:ANAC » details
Traded in other countries:AXP.Germany, ALXN.Switzerland, 0QZM.UK,
Alexion Pharmaceuticals Inc is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Alexion Pharmaceuticals Inc is a Delaware based company, incorporated in 1992. The Company is a bio-pharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company is also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. It operates in United States, Europe and Asia Pacific. It competes with companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and in other countries and regions, as well as a growing number of large pharmaceutical companies that are developing biotechnology products. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of products and product candidates, including Soliris, are subject to extensive regulation by governmental authorities in the United States, the European Union and other territories.

Ratios

vs
industry
vs
history
P/E(ttm) 177.04
ALXN's P/E(ttm) is ranked lower than
90% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.09 vs. ALXN: 177.04 )
Ranked among companies with meaningful P/E(ttm) only.
ALXN' s P/E(ttm) Range Over the Past 10 Years
Min: 13.92  Med: 78.42 Max: 1113.68
Current: 177.04
13.92
1113.68
Forward P/E 24.63
ALXN's Forward P/E is ranked lower than
59% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 21.32 vs. ALXN: 24.63 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 177.04
ALXN's PE(NRI) is ranked lower than
89% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 29.71 vs. ALXN: 177.04 )
Ranked among companies with meaningful PE(NRI) only.
ALXN' s PE(NRI) Range Over the Past 10 Years
Min: 13.96  Med: 78.85 Max: 1058
Current: 177.04
13.96
1058
Price/Owner Earnings (ttm) 92.85
ALXN's Price/Owner Earnings (ttm) is ranked lower than
77% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 34.88 vs. ALXN: 92.85 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ALXN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 15.74  Med: 71.00 Max: 1108.89
Current: 92.85
15.74
1108.89
P/B 3.55
ALXN's P/B is ranked lower than
53% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. ALXN: 3.55 )
Ranked among companies with meaningful P/B only.
ALXN' s P/B Range Over the Past 10 Years
Min: 3.14  Med: 10.57 Max: 166.91
Current: 3.55
3.14
166.91
P/S 10.31
ALXN's P/S is ranked higher than
57% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. ALXN: 10.31 )
Ranked among companies with meaningful P/S only.
ALXN' s P/S Range Over the Past 10 Years
Min: 9.12  Med: 16.63 Max: 929.17
Current: 10.31
9.12
929.17
PFCF 52.54
ALXN's PFCF is ranked lower than
71% of the 147 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. ALXN: 52.54 )
Ranked among companies with meaningful PFCF only.
ALXN' s PFCF Range Over the Past 10 Years
Min: 40  Med: 62.73 Max: 3326.67
Current: 52.54
40
3326.67
POCF 33.73
ALXN's POCF is ranked lower than
63% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 22.90 vs. ALXN: 33.73 )
Ranked among companies with meaningful POCF only.
ALXN' s POCF Range Over the Past 10 Years
Min: 29.93  Med: 49.63 Max: 83.31
Current: 33.73
29.93
83.31
EV-to-EBIT 51.09
ALXN's EV-to-EBIT is ranked lower than
78% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. ALXN: 51.09 )
Ranked among companies with meaningful EV-to-EBIT only.
ALXN' s EV-to-EBIT Range Over the Past 10 Years
Min: -115.8  Med: 46.20 Max: 499.4
Current: 51.09
-115.8
499.4
EV-to-EBITDA 36.02
ALXN's EV-to-EBITDA is ranked lower than
71% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. ALXN: 36.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALXN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -145  Med: 41.90 Max: 258.3
Current: 36.02
-145
258.3
PEG 4.94
ALXN's PEG is ranked lower than
67% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 2.22 vs. ALXN: 4.94 )
Ranked among companies with meaningful PEG only.
ALXN' s PEG Range Over the Past 10 Years
Min: 0.68  Med: 1.54 Max: 6.5
Current: 4.94
0.68
6.5
Shiller P/E 141.71
ALXN's Shiller P/E is ranked lower than
85% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 56.77 vs. ALXN: 141.71 )
Ranked among companies with meaningful Shiller P/E only.
ALXN' s Shiller P/E Range Over the Past 10 Years
Min: 125.54  Med: 308.29 Max: 5207
Current: 141.71
125.54
5207
Current Ratio 3.52
ALXN's Current Ratio is ranked lower than
59% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ALXN: 3.52 )
Ranked among companies with meaningful Current Ratio only.
ALXN' s Current Ratio Range Over the Past 10 Years
Min: 2.3  Med: 7.34 Max: 52.92
Current: 3.52
2.3
52.92
Quick Ratio 3.04
ALXN's Quick Ratio is ranked lower than
61% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. ALXN: 3.04 )
Ranked among companies with meaningful Quick Ratio only.
ALXN' s Quick Ratio Range Over the Past 10 Years
Min: 2.03  Med: 7.02 Max: 52.92
Current: 3.04
2.03
52.92
Days Inventory 402.98
ALXN's Days Inventory is ranked lower than
93% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 128.57 vs. ALXN: 402.98 )
Ranked among companies with meaningful Days Inventory only.
ALXN' s Days Inventory Range Over the Past 10 Years
Min: 202.61  Med: 292.91 Max: 959.95
Current: 402.98
202.61
959.95
Days Sales Outstanding 79.11
ALXN's Days Sales Outstanding is ranked lower than
61% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. ALXN: 79.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALXN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.74  Med: 106.12 Max: 339.23
Current: 79.11
70.74
339.23
Days Payable 70.31
ALXN's Days Payable is ranked higher than
57% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 57.77 vs. ALXN: 70.31 )
Ranked among companies with meaningful Days Payable only.
ALXN' s Days Payable Range Over the Past 10 Years
Min: 44.39  Med: 90.78 Max: 494.52
Current: 70.31
44.39
494.52

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.41
ALXN's Price/Projected FCF is ranked higher than
64% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 3.44 vs. ALXN: 2.41 )
Ranked among companies with meaningful Price/Projected FCF only.
ALXN' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.64  Med: 5.68 Max: 142.22
Current: 2.41
2.64
142.22
Price/Median PS Value 0.62
ALXN's Price/Median PS Value is ranked higher than
76% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ALXN: 0.62 )
Ranked among companies with meaningful Price/Median PS Value only.
ALXN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.37  Med: 1.22 Max: 50.5
Current: 0.62
0.37
50.5
Price/Peter Lynch Fair Value 7.08
ALXN's Price/Peter Lynch Fair Value is ranked lower than
91% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.76 vs. ALXN: 7.08 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ALXN' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.56  Med: 2.93 Max: 10.04
Current: 7.08
0.56
10.04
Earnings Yield (Greenblatt) (%) 1.99
ALXN's Earnings Yield (Greenblatt) (%) is ranked higher than
80% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. ALXN: 1.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALXN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 2.00 Max: 3
Current: 1.99
0.2
3
Forward Rate of Return (Yacktman) (%) 36.88
ALXN's Forward Rate of Return (Yacktman) (%) is ranked higher than
87% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 14.20 vs. ALXN: 36.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ALXN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -18.5  Med: 0.40 Max: 75.6
Current: 36.88
-18.5
75.6

More Statistics

Revenue (TTM) (Mil) $2,705
EPS (TTM) $ 0.72
Beta1.46
Short Percentage of Float2.94%
52-Week Range $110.56 - 208.88
Shares Outstanding (Mil)224.02

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 3,095 3,824 4,654
EPS ($) 5.12 6.94 8.82
EPS w/o NRI ($) 5.12 6.94 8.82
EPS Growth Rate
(3Y to 5Y Estimate)
20.00%
Dividends Per Share ($)
» More Articles for NAS:ALXN

Headlines

Articles On GuruFocus.com
Frank Sands Sells Visa, Baidu, Alibaba May 24 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 06 2016 
Baron Funds Comments on Alexion Pharmaceuticals Feb 08 2016 
Weekly CFO Sales Highlight: H&R Block, DISH Network, Alexion Pharmaceuticals Jan 03 2016 
Weekly CFO Sells Highlight: Tyson Foods, Alexion Pharmaceuticals, Gilead Sciences Dec 13 2015 
Weekly Insider Sells Highlights: CDW, Twitter, P&G, Alexion Pharmaceuticals Dec 10 2015 
Alexion Pharmaceuticals Loses Position in Swensen's Portfolio Dec 03 2015 
Jim Simons' Largest Adds of the 3rd Quarter Nov 13 2015 

More From Other Websites
Understanding Improvement in Vertex Pharmaceuticals’s PE Multiple Jul 25 2016
What’s behind the Recent Fall in Alexion’s Valuation Multiple? Jul 25 2016
Orkambi Launch Impacts Vertex Pharmaceuticals’s Major Revenue Contributor Jul 25 2016
How Kanuma Addition to Alexion’s Portfolio Impacts Its Earnings Jul 25 2016
Is Vertex Pharmaceuticals Exposed to Drug Pricing Risks? Jul 22 2016
How Alexion Plans to Fuel Strensiq Sales Jul 22 2016
How Can Alexion Stay ahead of the Competition with Soliris? Jul 22 2016
Wall Street Looks for Vertex Pharmaceuticals to Break Even in 2Q16 Jul 21 2016
Analysts Gauge Alexion Pharmaceuticals’ Return Potential Jul 21 2016
Will Alexion Pharmaceuticals’ 2Q16 Earnings Surprise? Jul 21 2016
Biotech: Steak, But No Sizzle Jul 15 2016
Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive... Jul 14 2016
Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive... Jul 14 2016
Amazon Target Primed; Top Banks Initiated Ahead Of Earnings Jul 13 2016
Alexion Pharmaceuticals (ALXN) Stock Gets ‘Outperform’ Rating at RBC Capital Jul 13 2016
16 Recently Upgraded Stocks (APD,ALXN,ADP,BHI) Jul 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)